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Abstract
Background Epinephrine remains the drug of choice for
cardiopulmonary resuscitation. The aim of the present study is
to assess whether the combination of vasopressin and
epinephrine, given their different mechanisms of action,
provides better results than epinephrine alone in
cardiopulmonary resuscitation.
Methods Ventricular fibrillation was induced in 22 Landrace/
Large-White piglets, which were left untreated for 8 minutes
before attempted resuscitation with precordial compression,
mechanical ventilation and electrical defibrillation. Animals were
randomized into 2 groups during cardiopulmonary resuscitation:
11 animals who received saline as placebo (20 ml dilution,
bolus) + epinephrine (0.02 mg/kg) (Epi group); and 11 animals
who received vasopressin (0.4 IU/kg/20 ml dilution, bolus) +
epinephrine (0.02 mg/kg) (Vaso-Epi group). Electrical
defibrillation was attempted after 10 minutes of ventricular
fibrillation.
Results Ten of 11 animals in the Vaso-Epi group restored
spontaneous circulation in comparison to only 4 of 11 in the Epi
group (p = 0.02). Aortic diastolic pressure, as well as, coronary
perfusion pressure were significantly increased (p  < 0.05)
during cardiopulmonary resuscitation in the Vaso-Epi group.
Conclusion The administration of vasopressin in combination
with epinephrine during cardiopulmonary resuscitation results in
a drastic improvement in the hemodynamic parameters
necessary for the return of spontaneous circulation.
Introduction
Cardiac arrest affects more than 700,000 people per year in
Europe [1-3]. Ventricular fibrillation (VF) is used to treat up to
40% of the cases when help arrives [4-6]. VF requires imme-
diate bystander cardiopulmonary resuscitation (CPR) and
electrical defibrillation [7].
The preferred drug for more than 100 years for use during VF
has been epinephrine (adrenaline) [8]. Epinephrine's vasocon-
strictive action results in a rise in the aortic pressure, thus
increasing the coronary perfusion pressure (CPP) [9,10].
Vasopressin also has a vasoconstrictive action in the vascular
network of the skeletal muscles, bowel, fat tissue, skin and, to
a lesser degree, the coronary and renal vessels, while it
causes vasodilation in the brain vessels. This results in an
increase of the coronary perfusion pressure and, in general, an
increase of blood flow to the vital organs without causing a
dramatic increase in the myocardial oxygen consumption
[11,12]. The aim of the present study is to assess whether the
combination of vasopressin with epinephrine (Vaso-Epi com-
bination) would increase initial resuscitation success demon-
strated by the return of spontaneous circulation (ROSC).
Materials and methods
After approval by the General Directorate of Veterinary Serv-
ices, 22 Landrace/Large-White piglets of both sexes, all from
the same breeder, with an average weight of 19 ± 2 kg were
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included in the study. Prior to any procedure, animals were
randomized into two groups with the use of a sealed envelope
indicating the animal's assignment to either the Epi group (11
animals; saline as placebo (10 ml dilution, bolus) + epine-
phrine (0.02 mg/kg)) or the Vaso-Epi group (11 animals; vaso-
pressin (0.4 IU/kg/10 ml dilution, bolus) + epinephrine (0.02
mg/kg)). The study was blinded as to the medication used.
The experimental protocol has been described previously [13].
Briefly, anesthesia was induced with an intravenous bolus of
propofol and the pigs were intubated with a 4.5 or 5 mm
endotracheal tube (Portex, ID Smiths Medical, Keene, NH,
USA). Additional propofol, cis-Atracurium and Fentanyl were
administered immediately before connecting the animals to
the automatic ventilator (ventiPac Sims pneuPac Ltd, Luton
UK) with oxygen (FiO2 21%). Propofol infusion and additional
doses of cis-Atracurium and Fentanyl followed. The animals
were ventilated with the aid of a volume-controlled ventilator
(total tidal volume 10 ml/kg). End-tidal CO2 was monitored
(AG-400R, Nihon Kohden Italia, Bergamo, Italy) and the respi-
ratory frequency was adjusted to maintain PETCO2 at 35 to 40
mmHg. Cardiac rhythm was monitored with an electrocardio-
gram (Mennen Medical, Envoy, Papapostolou, Athens,
Greece).
Both of the internal jugular veins and the left carotid artery
were prepared surgically. The systolic and diastolic aortic
pressure were monitored continuously by inserting a normal
saline-filled (model 6523, USCI CR, Bart Inc, Athens, Greece)
arterial catheter into the descending thoracic aorta via the right
common carotid artery. Both internal jugular veins were cathe-
terized with a 6F sheath and a Swan-Ganz catheter (Opticath
5.5 F, 75 cm Abbott, Ethicon Mersilk™, Ladakis, Athens,
Greece) was inserted into the right atrium for continuous
measurement of systolic and diastolic right atrial pressure via
the left jugular vein. The pressure was monitored using con-
ventional external pressure transducers (Abbott Critical Care
Systems, Transpac IV, Athens, Greece). CPP was calculated
as the difference between diastolic aortic pressure and time-
coincident mean right atrial pressure.
After allowing animals to stabilize for 40 minutes, baseline
measurements were obtained and then a 5F flow-directed
pacing catheter (Pacel™; 100 cm, St Jude Medical, Ladakis,
Athens, Greece) was inserted through the right internal jugular
vein into the apex of the right ventricle. VF was induced via a 9
V lithium battery. VF was confirmed electrocardiographically
and in combination with the sudden drop of mean arterial pres-
sure as described previously [13].
Immediately following confirmation of VF, mechanical ventila-
tion and propofol infusion were ceased. Animals were left
untreated for 8 minutes, representing the average time it takes
for emergency medical services to arrive [14].
Resuscitation procedures were started by setting inspired oxy-
gen concentration to 100%, followed by drug administration.
All drugs were administered via the lateral auricular vein, thus
simulating a peripheral vein via which drugs are administered
in cardiac arrest victims in an emergency setting. Precordial
compression began with a mechanical chest compressor
(Thumper, Michigan instruments, Talon Court, SE, USA) for 2
minutes. Compressions were maintained at a rate of 100/
minute. After 2 minutes of precordial compression, defibrilla-
tion was attempted with 4 J/kg monophasic waveform shock
(Porta Pak/90-Medical Research Laboratories Inc, Buffalo
Grove, IL, USA). In the case of failure to convert to a cardiac
rhythm compatible with pulse, precordial compression was
resumed for 2 minutes before the delivery of a second shock.
The endpoints were defined as ROSC, asystole or persisting
VF after the third defibrillation attempt. ROSC was defined as
the presence of an organized cardiac rhythm with a mean arte-
rial pressure of at least 60 mmHg for a minimum of 5 minutes.
The successfully resuscitated animals were monitored for 60
minutes while anesthesia was maintained. All animals were
humanely killed by an intravenous overdose of thiopental (2 g).
The study was powered statistically to detect changes in
ROSC. Data are expressed as the mean ± standard deviation
(SD) for continuous variables and as percentages for categor-
ical data. The Kolmogorov-Smirnov test was utilized for nor-
mality analysis of the parameters. Comparisons of continuous
variables were analyzed using Student's t-test and the Mann-
Whitney non-parametric test, as appropriate. Comparisons of
categorical variables were analyzed using Fisher's exact test.
Paired samples t-test and Wilcoxon tests were used for the
comparison of different time measurement of parameters for
each group. A comparison of the percentage change from
baseline of the parameters during the observation period
between two groups was made using the Mann-Whitney test.
Moreover, using the analysis of covariance model the differ-
ence between groups was compared for all parameters at
each time point controlling for baseline difference using the
value of parameter at each time point as the dependent varia-
ble and baseline measurements as covariates.
Differences were considered as statistically significant if the
null hypothesis could be rejected with >95% confidence (p <
0.05). All analyses were conducted using SPSS, version
13.00 (SPSS Inc, Chicago, IL, USA).
Results
Baseline hemodynamic measurements did not differ between
the two groups (Table 1). By the end of the eighth minute of
VF, mean arterial pressure decreased from 89.3 ± 7.57 to
22.5 ± 3.31 mmHg in Epi group and from 89.0 ± 12.06 to
20.77 ± 3.96 mmHg in the Vaso-Epi group (p = 0.316). CPP
declined rapidly and was 0.60 ± 0.96 mmHg in Epi group andAvailable online http://ccforum.com/content/12/2/R40
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0.77 ± 0.83 mmHg in Vaso-Epi group (p = 0.675) during the
eighth minute of untreated VF in both groups.
In the first minute of CPR, CPP rose significantly in the Vaso-
Epi group and remained statistically higher in the second
minute of CPR (Figure 1). A significant increase in diastolic
aortic pressure was also noted between groups (Figure 2).
ROSC was observed in 4 animals in Epi group, while 10 ani-
mals achieved ROSC in the Vaso-Epi group (p = 0.02). More
specifically, 4 animals in Epi group were successfully resusci-
tated after the first defibrillation and no further animals
achieved ROSC in the following defibrillation attempts. In the
Vaso-Epi group, 10 animals were resuscitated after the first
defibrillation and 1 animal failed to achieve ROSC. This animal,
without any external stimuli, presented with acute complete
atrioventricular block, followed by non-sustained ventricular
tachycardia and, finally, pulselles electrical activity. In this ani-
mal, an autopsy revealed pneumonia, whereas routine autopsy
of the rest of the animals in both groups showed no evidence
of pathology in the cardiopulmonary system. Furthermore, the
total number of shocks in Epi group was 25 compared with 12
in Vaso-Epi group.
All animals that were resuscitated successfully were moni-
tored for 1 hour. Table 2 summarizes the parameters meas-
ured during the 60th minute after ROSC. No statistically
significant difference was found between the two groups dur-
ing the whole post-resuscitation period.
Discussion
In case of VF, the Advanced Life Support Guidelines of the
European Resuscitation Council recommend the periodic use
of epinephrine if two initial defibrillations have failed [15]. The
use of a vasopressor is thought to be beneficial in cardiac
arrest by improving cardiac and brain blood flow during CPR
[16-18].
Epineprhine increases CPP via systemic arteriolar vasocon-
striction, which maintains peripheral vascular tone and pre-
vents arteriolar collapse [19]. Furthermore, during
experimental and clinical cardiac arrest, endogenous catecho-
lamine concentrations are extremely high (up to 170 times nor-
mal levels in an animal model of VF) [20]. Thus, evidence
suggests that epinephrine may be helpful in CPR, especially in
short-term survival [15,19].
Vasopressin, an endogenous peptide, is a potent vasopressor
agent and has been shown to be beneficial in CPR. Via the V1
receptors, it stimulates the contraction of vascular smooth
muscles, resulting in peripheral vasoconstriction and
increased blood pressure. Via the V2 receptors, vasopressin
Table 1
Baseline variables in the two different groups
HR (bpm) SAP (mmHg) DAP (mmHg) MAP (mmHg) MRAP (mmHg) CPP
Epi group 108 ± 17 104 ± 8 78 ± 12 89 ± 8 11 ± 1 67 ± 11
Vaso-Epi group 123 ± 16 104 ± 12 82 ± 12 91 ± 16 11 ± 2 75 ± 13
p-value 0.084 0.968 0.479 0.948 0.777 0.193
CPP = coronary perfusion pressure; DAP = diastolic aortic pressure; HR = heart rate; MAP = mean aortic pressure; MRAP = mean right atrial 
pressure; SAP = systolic aortic pressure.
Figure 1
Coronary perfusion pressure (CPP) fluctuation during the experiment Coronary perfusion pressure (CPP) fluctuation during the experi-
ment. DF = defibrillation; CPR = cardiopulmonary resuscitation (*p < 
0.0001 Vaso-Epi group versus Epi group).
Figure 2
Diastolic aortic pressure (DAP) fluctuation during the experiment Diastolic aortic pressure (DAP) fluctuation during the experiment. 
DF = defibrillation; CPR = cardiopulmonary resuscitation (*p < 0.0001 
Vaso-Epi group versus Epi group).Critical Care    Vol 12 No 2    Stroumpoulis et al.
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possibly induces vasodilation [21-23]. Unlike epinephrine, it is
resistant to the effects of acidosis [24,25]. Endogenous vaso-
pressin levels were found to be higher in survivors of cardiac
arrest than those who died [26-28].
However, the recent international literature is not very encour-
aging in the use of vasopressin as a single agent of choice for
cardiac arrest. On a systematic review and meta-analysis of
1,519 patients with cardiac arrest from 5 randomized control-
led trials, the results demonstrate that there is no clear advan-
tage of vasopressin over epinephrine and that vasopressin
should not be recommended on resuscitation protocols until
more solid human data on its superiority are available [29].
In a multicenter trial, the effects of vasopressin were similar to
those of epinephrine in the management of cardiac arrest and
pulseless electrical activity (PEA) [17]. On the other hand,
most of the porcine models of cardiac arrest give encouraging
results. Biondi-Zoccai et al, in a meta-analysis including 33 ani-
mal studies, showed that vasopressin appeared to be superior
to both placebo and epinephrine in VF cardiac arrest [30].
These seemingly contradictory findings may be explained by
the fact that many of the studies do not take into account a
subgroup analysis such as the distinction between VF, PEA
and asystole. Another fact that should be taken into consider-
ation is that many experimental models refer to asphyxial car-
diac arrest, which implies a different mechanism of induction
of cardiac arrest than electrical stimulation, and also leads to
a severely hypoxic myocardium. All of these facts may suggest
that the usual approach of pharmacological CPR management
to administer identical drugs and dosages for patients with
cardiac arrest caused by different factors may have to be
reconsidered. Furthermore, it is possible that when the degree
of ischemia is fundamental, as during asphyxia, or when
advanced cardiac life support is prolonged, a combination of
vasopressin with epinephrine may be beneficial [31]. Wenzel
et al [17] also provided recent supported for this finding in a
clinical trial where the Vaso-Epi patient subgroup had signifi-
cantly higher ROSC and hospital discharge rates. This finding
may indicate that the interactions among vasopressin, epine-
phrine and the underlying degree of ischemia during CPR may
be more complex than was thought previously [17]. Even if the
Vaso-Epi subset of patients in the aforementioned study was
fortuitous, our data also show a stronger vasoconstrictive
effect of the combination of the two drugs in comparison to
epinephrine alone in the first minute of CPR with an increase
of CPP. This increase was further attenuated in the second
minute when diastolic aortic pressure and CPP are signifi-
cantly increased.
There are experimental models indicating that an epinephrine-
vasopressin combination works better [32-34]. A secondary
analysis [17] of a clinical retrospective out-of-hospital cardiac
arrest study [18] drew the same conclusions. In our study we
have taken two points stated previously by other authors into
consideration: first, that vasopressin has greater activity than
epinephrine under the hypoxic and acidic conditions of a pro-
longed cardiac arrest [35]; and, second, that its V2-mediated
vasodilatory effect could improve the end-organ hypoper-
fusion resulting by epinephrine and catecholamine stimulation
[19].
The institution of effective external cardiac compressions
restores a pressure gradient between the aorta and the right
atrium with a return of blood flow [36]. Chest compressions
appear to be the most important factor, both in human and ani-
mal studies, and even short interruptions decrease CPP dra-
matically. In previous studies, CPP has been found to be the
key determinant for successful defibrillation in humans and var-
ious animal models [9].
The quality of chest compressions should not be overlooked in
the interpretation of the results of clinical studies. Chest com-
pressions in animal models are standardized and are usually
delivered mechanically. On the other hand, chest compres-
sions in clinical studies are usually of poor quality [37,38]. The
large clinical vasopressin studies were performed before prob-
lems in out-of-hospital CPR quality were recognized, therefore
this factor should also be taken into consideration in the inter-
pretation of the clinical outcome in vasopressin studies.
The authors recognize several limitations in the interpretation
of the present findings. The study was conducted on appar-
ently healthy pigs and its direct application to human victims of
cardiac arrest has yet to be addressed. Furthermore, between-
species differences in the effects of vasopressin have not
been evaluated in the present study. For example, there are dif-
ferent receptors in pigs (lysine vasopressin) and in humans
Table 2
Parameters measured during the 60th minute after the return of spontaneous circulation
HR (bpm) SAP (mmHg) DAP (mmHg) MAP (mmHg) MRAP (mmHg)
Epi group 146 ± 31 103 ± 24 77 ± 25 90 ± 26 16 ± 3
Vaso-Epi group 135 ± 17 88 ± 20 69 ± 14 78 ± 16 14 ± 4
P 0.440 0.287 0.495 0.26 0.541
DAP = diastolic aortic pressure; HR = heart rate; MAP = mean aortic pressure; MRAP = mean right atrial pressure; SAP = systolic aortic 
pressure.Available online http://ccforum.com/content/12/2/R40
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(arginin vasopressin) [34]. In addition, the experimental ani-
mals were anesthetized and the potential interactions of the
different agents were not assessed.
Conclusion
Our study has demonstrated that the combination of epine-
phrine and vasopressin in the treatment of VF cardiac arrest
improved perfusion pressures and short-term survival, in com-
parison to the single use of epinephrine. This study adds some
evidence to the existing literature of the epinephrine-vaso-
pressin combination benefits and further evaluation of these
results should be undertaken in the future.
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